Subsequent malignancies after allogeneic hematopoietic stem cell transplantation.

Area of Science:

• Hematology
• Oncology
• Transplantation Medicine

Background:

• Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a life-saving procedure.
• Late complications, including secondary malignancies, can significantly impact long-term patient outcomes.
• Understanding risk factors for these malignancies is crucial for improving patient care.

Purpose of the Study:

• To evaluate the incidence and risk factors for post-transplant lymphoproliferative disease (PTLD) and solid tumors after allo-HSCT.
• To identify specific patient groups at higher risk for developing these late complications.

Main Methods:

• Retrospective analysis of 979 patients who underwent allo-HSCT.
• Evaluation of subsequent development of PTLD and solid tumors.
• Statistical analysis to identify risk factors, including transplant indication and chronic graft-versus-host disease (GVHD).

Main Results:

• 15 (1.5%) patients developed subsequent malignancies (3 PTLD, 12 solid tumors).
• Median time to PTLD was 9 months, and to solid tumors was 93 months.
• Patients with benign hematological diseases as indication (7.4% at 5 years) and chronic GVHD ≥1 year (3.7%) had significantly higher risks of subsequent malignancy.

Conclusions:

• Subsequent malignancies are a notable late complication after allo-HSCT.
• Benign hematological diseases as transplant indication and chronic GVHD ≥1 year are significant risk factors for developing subsequent malignancies.
• Long-term surveillance and risk-stratified management are essential for patients post-allo-HSCT.